Clinical Trial Update: TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV [Phase 3]

View source ↗

Summary

A Phase 3 study providing continued access to darunavir/ritonavir for HIV-1 infected individuals from prior studies; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-1 Infections

Drugs mentioned

• darunavir/ritonavir (darunavir/ritonavir)

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: HIV-1 Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-10-31